Wednesday, July 8, 2026

pharma · Fatty Liver · Inflammatory Disease · GLMD

Galmed Pharmaceuticals

Galmed Pharmaceuticals is a pharma organization headquartered in Tel Aviv, USA. It trades on NYSE under ticker GLMD. Primary therapeutic focus areas include Fatty Liver, Inflammatory Disease, Nonalcoholic Steatohepatitis

16 Ze’ev Tiomkin Street, Tel Aviv, 6578317, IL, USA HQ
2000 Founded
10 Employees
Public company Type
GLMD · NYSE Ticker
Company details
Status
Public
HQ
16 Ze’ev Tiomkin Street, Tel Aviv, 6578317, IL, USA
Founded
2000
Employees
10
Programs
13
Drugs
5
Patents
11
Clinical program

Aramchol free acid

Phase 3 · small molecule · Nonalcoholic Steatohepatitis (NASH)

Aramchol free acid for Nonalcoholic Steatohepatitis (NASH) is a Phase 3 program (small_molecule) at Galmed Pharmaceuticals with 1 ClinicalTrials.gov record(s).

← All Galmed Pharmaceuticals projects Phase 3 small molecule on hold

Internal code Aramchol-018

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Galmed Pharmaceuticals
Phase
Phase 3
Modality
small_molecule
Indication
Nonalcoholic Steatohepatitis (NASH)
Status
on_hold
Trials
1